Clinical characteristics and human leukocyte antigens in patients with immune checkpoint inhibitor-induced type 1 diabetes and pituitary dysfunction: a single center prospective study
Purpose Immune checkpoint inhibitor (ICI) induced type 1 diabetes (T1D) and pituitary dysfunction are life-threatening adverse events, yet there is little clinical data available. We aimed to investigate the clinical characteristics of patients with these adverse events and report their human leukoc...
Gespeichert in:
| Veröffentlicht in: | Endocrine 2023-09, Vol.81 (3), p.477-483 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 483 |
|---|---|
| container_issue | 3 |
| container_start_page | 477 |
| container_title | Endocrine |
| container_volume | 81 |
| creator | Hara, Natsuko Suwanai, Hirotsugu Yakou, Fumiyoshi Ishii, Keitaro Iwasaki, Hajime Abe, Hironori Shikuma, Jumpei Sakai, Hiroyuki Miwa, Takashi Suzuki, Ryo |
| description | Purpose
Immune checkpoint inhibitor (ICI) induced type 1 diabetes (T1D) and pituitary dysfunction are life-threatening adverse events, yet there is little clinical data available. We aimed to investigate the clinical characteristics of patients with these adverse events and report their human leukocyte antigen (HLA) profile to determine its relevance.
Methods
This is a single-center prospective study. We enrolled patients with cancers who were administered ICI and diagnosed as ICI induced T1D (ICI-T1D) and pituitary dysfunction (ICI-PD). Clinical data and extracted DNA from blood samples were collected. HLA typing was performed using next-generation sequencing. We compared our results with those previously reported in healthy controls and investigated the correlation between HLA and the occurrence of ICI-T1D and ICI-PD.
Results
We identified 914 patients treated with ICI in our facility from 1st September, 2017 to 30th June, 2022. Six of these patients developed T1D and 15 developed pituitary dysfunction. The duration from the initiation of ICI treatment to the onset of T1D or pituitary dysfunction averaged 492 ± 196 days and 191 ± 169 days. Among the six patients with T1D, two were positive for anti-GAD antibody. The frequencies of HLA-DR11, -Cw10, -B61, -DRB1*11:01, and -C*03:04 were significantly higher in patients with ICI-T1D than in controls. The frequencies of HLA-DR15 and -DRB*15:02 were significantly higher in patients with ICI-PD than in controls.
Conclusion
This study revealed the clinical characteristics of ICI-T1D and ICI-PD and the association between specific HLAs and these adverse events. |
| doi_str_mv | 10.1007/s12020-023-03394-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2813560656</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2813560656</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-436357b38b83d002665d41e320dc61fdb2701621d855fa9d1f286ca5d74d49b13</originalsourceid><addsrcrecordid>eNp9kcmO1TAQRSMEogf4ARbIEhs2AQ-Jk7BDT9AgtcQG1pFjV96r7sQJHkD5Mn6PgjSDWLCy5Tp1b5VvUTwR_IXgvHkZheSSl1yqkivVVWV7rzgXdd2VnOr3_7qfFRcx3nAupdTNw-JMNaJpleDnxbfDhB6tmZg9mWBsgoAxoY3MeMdOeTaeTZBvF7sloLeER_CRoWerSQg-RfYV04nhPGcPJAL2dl3QJ0JOOGBaQoneZQuOpW0FJphDM0CC3WHFlDGZsDG3xTF7m3Dxr5hhEf1xIkGygMDWsMQVqPgFWEzZbY-KB6OZIjy-Oy-LT2_ffDy8K68_XL0_vL4ubSW6VFZKq7oZVDu0ytH-WteuEqAkd1aL0Q2y4UJL4dq6Hk3nxChbbU3tmspV3SDUZfF816UJPmeIqZ8xWpgm42HJsZetULXmutaEPvsHvVly8DQdUZWWjWxlQ5TcKUsrxQBjvwac6QN6wfsfsfZ7rD3F2v-MtW-p6emddB5mcL9bfuVIgNqBSCV_hPDH-z-y3wHmQLFF</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2846272827</pqid></control><display><type>article</type><title>Clinical characteristics and human leukocyte antigens in patients with immune checkpoint inhibitor-induced type 1 diabetes and pituitary dysfunction: a single center prospective study</title><source>SpringerLink Journals - AutoHoldings</source><creator>Hara, Natsuko ; Suwanai, Hirotsugu ; Yakou, Fumiyoshi ; Ishii, Keitaro ; Iwasaki, Hajime ; Abe, Hironori ; Shikuma, Jumpei ; Sakai, Hiroyuki ; Miwa, Takashi ; Suzuki, Ryo</creator><creatorcontrib>Hara, Natsuko ; Suwanai, Hirotsugu ; Yakou, Fumiyoshi ; Ishii, Keitaro ; Iwasaki, Hajime ; Abe, Hironori ; Shikuma, Jumpei ; Sakai, Hiroyuki ; Miwa, Takashi ; Suzuki, Ryo</creatorcontrib><description>Purpose
Immune checkpoint inhibitor (ICI) induced type 1 diabetes (T1D) and pituitary dysfunction are life-threatening adverse events, yet there is little clinical data available. We aimed to investigate the clinical characteristics of patients with these adverse events and report their human leukocyte antigen (HLA) profile to determine its relevance.
Methods
This is a single-center prospective study. We enrolled patients with cancers who were administered ICI and diagnosed as ICI induced T1D (ICI-T1D) and pituitary dysfunction (ICI-PD). Clinical data and extracted DNA from blood samples were collected. HLA typing was performed using next-generation sequencing. We compared our results with those previously reported in healthy controls and investigated the correlation between HLA and the occurrence of ICI-T1D and ICI-PD.
Results
We identified 914 patients treated with ICI in our facility from 1st September, 2017 to 30th June, 2022. Six of these patients developed T1D and 15 developed pituitary dysfunction. The duration from the initiation of ICI treatment to the onset of T1D or pituitary dysfunction averaged 492 ± 196 days and 191 ± 169 days. Among the six patients with T1D, two were positive for anti-GAD antibody. The frequencies of HLA-DR11, -Cw10, -B61, -DRB1*11:01, and -C*03:04 were significantly higher in patients with ICI-T1D than in controls. The frequencies of HLA-DR15 and -DRB*15:02 were significantly higher in patients with ICI-PD than in controls.
Conclusion
This study revealed the clinical characteristics of ICI-T1D and ICI-PD and the association between specific HLAs and these adverse events.</description><identifier>ISSN: 1559-0100</identifier><identifier>ISSN: 1355-008X</identifier><identifier>EISSN: 1559-0100</identifier><identifier>DOI: 10.1007/s12020-023-03394-8</identifier><identifier>PMID: 37178310</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adverse events ; Antigens ; Diabetes ; Diabetes mellitus (insulin dependent) ; Drb1 protein ; Endocrinology ; Histocompatibility antigen HLA ; Humanities and Social Sciences ; Immune checkpoint inhibitors ; Internal Medicine ; Leukocytes ; Medicine ; Medicine & Public Health ; multidisciplinary ; Next-generation sequencing ; Original Article ; Patients ; Pituitary ; Science ; Tissue typing</subject><ispartof>Endocrine, 2023-09, Vol.81 (3), p.477-483</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-436357b38b83d002665d41e320dc61fdb2701621d855fa9d1f286ca5d74d49b13</citedby><cites>FETCH-LOGICAL-c419t-436357b38b83d002665d41e320dc61fdb2701621d855fa9d1f286ca5d74d49b13</cites><orcidid>0000-0001-9102-630X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12020-023-03394-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12020-023-03394-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37178310$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hara, Natsuko</creatorcontrib><creatorcontrib>Suwanai, Hirotsugu</creatorcontrib><creatorcontrib>Yakou, Fumiyoshi</creatorcontrib><creatorcontrib>Ishii, Keitaro</creatorcontrib><creatorcontrib>Iwasaki, Hajime</creatorcontrib><creatorcontrib>Abe, Hironori</creatorcontrib><creatorcontrib>Shikuma, Jumpei</creatorcontrib><creatorcontrib>Sakai, Hiroyuki</creatorcontrib><creatorcontrib>Miwa, Takashi</creatorcontrib><creatorcontrib>Suzuki, Ryo</creatorcontrib><title>Clinical characteristics and human leukocyte antigens in patients with immune checkpoint inhibitor-induced type 1 diabetes and pituitary dysfunction: a single center prospective study</title><title>Endocrine</title><addtitle>Endocrine</addtitle><addtitle>Endocrine</addtitle><description>Purpose
Immune checkpoint inhibitor (ICI) induced type 1 diabetes (T1D) and pituitary dysfunction are life-threatening adverse events, yet there is little clinical data available. We aimed to investigate the clinical characteristics of patients with these adverse events and report their human leukocyte antigen (HLA) profile to determine its relevance.
Methods
This is a single-center prospective study. We enrolled patients with cancers who were administered ICI and diagnosed as ICI induced T1D (ICI-T1D) and pituitary dysfunction (ICI-PD). Clinical data and extracted DNA from blood samples were collected. HLA typing was performed using next-generation sequencing. We compared our results with those previously reported in healthy controls and investigated the correlation between HLA and the occurrence of ICI-T1D and ICI-PD.
Results
We identified 914 patients treated with ICI in our facility from 1st September, 2017 to 30th June, 2022. Six of these patients developed T1D and 15 developed pituitary dysfunction. The duration from the initiation of ICI treatment to the onset of T1D or pituitary dysfunction averaged 492 ± 196 days and 191 ± 169 days. Among the six patients with T1D, two were positive for anti-GAD antibody. The frequencies of HLA-DR11, -Cw10, -B61, -DRB1*11:01, and -C*03:04 were significantly higher in patients with ICI-T1D than in controls. The frequencies of HLA-DR15 and -DRB*15:02 were significantly higher in patients with ICI-PD than in controls.
Conclusion
This study revealed the clinical characteristics of ICI-T1D and ICI-PD and the association between specific HLAs and these adverse events.</description><subject>Adverse events</subject><subject>Antigens</subject><subject>Diabetes</subject><subject>Diabetes mellitus (insulin dependent)</subject><subject>Drb1 protein</subject><subject>Endocrinology</subject><subject>Histocompatibility antigen HLA</subject><subject>Humanities and Social Sciences</subject><subject>Immune checkpoint inhibitors</subject><subject>Internal Medicine</subject><subject>Leukocytes</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>multidisciplinary</subject><subject>Next-generation sequencing</subject><subject>Original Article</subject><subject>Patients</subject><subject>Pituitary</subject><subject>Science</subject><subject>Tissue typing</subject><issn>1559-0100</issn><issn>1355-008X</issn><issn>1559-0100</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kcmO1TAQRSMEogf4ARbIEhs2AQ-Jk7BDT9AgtcQG1pFjV96r7sQJHkD5Mn6PgjSDWLCy5Tp1b5VvUTwR_IXgvHkZheSSl1yqkivVVWV7rzgXdd2VnOr3_7qfFRcx3nAupdTNw-JMNaJpleDnxbfDhB6tmZg9mWBsgoAxoY3MeMdOeTaeTZBvF7sloLeER_CRoWerSQg-RfYV04nhPGcPJAL2dl3QJ0JOOGBaQoneZQuOpW0FJphDM0CC3WHFlDGZsDG3xTF7m3Dxr5hhEf1xIkGygMDWsMQVqPgFWEzZbY-KB6OZIjy-Oy-LT2_ffDy8K68_XL0_vL4ubSW6VFZKq7oZVDu0ytH-WteuEqAkd1aL0Q2y4UJL4dq6Hk3nxChbbU3tmspV3SDUZfF816UJPmeIqZ8xWpgm42HJsZetULXmutaEPvsHvVly8DQdUZWWjWxlQ5TcKUsrxQBjvwac6QN6wfsfsfZ7rD3F2v-MtW-p6emddB5mcL9bfuVIgNqBSCV_hPDH-z-y3wHmQLFF</recordid><startdate>20230901</startdate><enddate>20230901</enddate><creator>Hara, Natsuko</creator><creator>Suwanai, Hirotsugu</creator><creator>Yakou, Fumiyoshi</creator><creator>Ishii, Keitaro</creator><creator>Iwasaki, Hajime</creator><creator>Abe, Hironori</creator><creator>Shikuma, Jumpei</creator><creator>Sakai, Hiroyuki</creator><creator>Miwa, Takashi</creator><creator>Suzuki, Ryo</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9102-630X</orcidid></search><sort><creationdate>20230901</creationdate><title>Clinical characteristics and human leukocyte antigens in patients with immune checkpoint inhibitor-induced type 1 diabetes and pituitary dysfunction: a single center prospective study</title><author>Hara, Natsuko ; Suwanai, Hirotsugu ; Yakou, Fumiyoshi ; Ishii, Keitaro ; Iwasaki, Hajime ; Abe, Hironori ; Shikuma, Jumpei ; Sakai, Hiroyuki ; Miwa, Takashi ; Suzuki, Ryo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-436357b38b83d002665d41e320dc61fdb2701621d855fa9d1f286ca5d74d49b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adverse events</topic><topic>Antigens</topic><topic>Diabetes</topic><topic>Diabetes mellitus (insulin dependent)</topic><topic>Drb1 protein</topic><topic>Endocrinology</topic><topic>Histocompatibility antigen HLA</topic><topic>Humanities and Social Sciences</topic><topic>Immune checkpoint inhibitors</topic><topic>Internal Medicine</topic><topic>Leukocytes</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>multidisciplinary</topic><topic>Next-generation sequencing</topic><topic>Original Article</topic><topic>Patients</topic><topic>Pituitary</topic><topic>Science</topic><topic>Tissue typing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hara, Natsuko</creatorcontrib><creatorcontrib>Suwanai, Hirotsugu</creatorcontrib><creatorcontrib>Yakou, Fumiyoshi</creatorcontrib><creatorcontrib>Ishii, Keitaro</creatorcontrib><creatorcontrib>Iwasaki, Hajime</creatorcontrib><creatorcontrib>Abe, Hironori</creatorcontrib><creatorcontrib>Shikuma, Jumpei</creatorcontrib><creatorcontrib>Sakai, Hiroyuki</creatorcontrib><creatorcontrib>Miwa, Takashi</creatorcontrib><creatorcontrib>Suzuki, Ryo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Endocrine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hara, Natsuko</au><au>Suwanai, Hirotsugu</au><au>Yakou, Fumiyoshi</au><au>Ishii, Keitaro</au><au>Iwasaki, Hajime</au><au>Abe, Hironori</au><au>Shikuma, Jumpei</au><au>Sakai, Hiroyuki</au><au>Miwa, Takashi</au><au>Suzuki, Ryo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical characteristics and human leukocyte antigens in patients with immune checkpoint inhibitor-induced type 1 diabetes and pituitary dysfunction: a single center prospective study</atitle><jtitle>Endocrine</jtitle><stitle>Endocrine</stitle><addtitle>Endocrine</addtitle><date>2023-09-01</date><risdate>2023</risdate><volume>81</volume><issue>3</issue><spage>477</spage><epage>483</epage><pages>477-483</pages><issn>1559-0100</issn><issn>1355-008X</issn><eissn>1559-0100</eissn><abstract>Purpose
Immune checkpoint inhibitor (ICI) induced type 1 diabetes (T1D) and pituitary dysfunction are life-threatening adverse events, yet there is little clinical data available. We aimed to investigate the clinical characteristics of patients with these adverse events and report their human leukocyte antigen (HLA) profile to determine its relevance.
Methods
This is a single-center prospective study. We enrolled patients with cancers who were administered ICI and diagnosed as ICI induced T1D (ICI-T1D) and pituitary dysfunction (ICI-PD). Clinical data and extracted DNA from blood samples were collected. HLA typing was performed using next-generation sequencing. We compared our results with those previously reported in healthy controls and investigated the correlation between HLA and the occurrence of ICI-T1D and ICI-PD.
Results
We identified 914 patients treated with ICI in our facility from 1st September, 2017 to 30th June, 2022. Six of these patients developed T1D and 15 developed pituitary dysfunction. The duration from the initiation of ICI treatment to the onset of T1D or pituitary dysfunction averaged 492 ± 196 days and 191 ± 169 days. Among the six patients with T1D, two were positive for anti-GAD antibody. The frequencies of HLA-DR11, -Cw10, -B61, -DRB1*11:01, and -C*03:04 were significantly higher in patients with ICI-T1D than in controls. The frequencies of HLA-DR15 and -DRB*15:02 were significantly higher in patients with ICI-PD than in controls.
Conclusion
This study revealed the clinical characteristics of ICI-T1D and ICI-PD and the association between specific HLAs and these adverse events.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>37178310</pmid><doi>10.1007/s12020-023-03394-8</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-9102-630X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1559-0100 |
| ispartof | Endocrine, 2023-09, Vol.81 (3), p.477-483 |
| issn | 1559-0100 1355-008X 1559-0100 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2813560656 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Adverse events Antigens Diabetes Diabetes mellitus (insulin dependent) Drb1 protein Endocrinology Histocompatibility antigen HLA Humanities and Social Sciences Immune checkpoint inhibitors Internal Medicine Leukocytes Medicine Medicine & Public Health multidisciplinary Next-generation sequencing Original Article Patients Pituitary Science Tissue typing |
| title | Clinical characteristics and human leukocyte antigens in patients with immune checkpoint inhibitor-induced type 1 diabetes and pituitary dysfunction: a single center prospective study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T10%3A55%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20characteristics%20and%20human%20leukocyte%20antigens%20in%20patients%20with%20immune%20checkpoint%20inhibitor-induced%20type%201%20diabetes%20and%20pituitary%20dysfunction:%20a%20single%20center%20prospective%20study&rft.jtitle=Endocrine&rft.au=Hara,%20Natsuko&rft.date=2023-09-01&rft.volume=81&rft.issue=3&rft.spage=477&rft.epage=483&rft.pages=477-483&rft.issn=1559-0100&rft.eissn=1559-0100&rft_id=info:doi/10.1007/s12020-023-03394-8&rft_dat=%3Cproquest_cross%3E2813560656%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2846272827&rft_id=info:pmid/37178310&rfr_iscdi=true |